ChemoCentryx (CCXI) Expected to Announce Earnings of -$0.29 Per Share
Wall Street analysts predict that ChemoCentryx (NASDAQ:CCXI) will report earnings of ($0.29) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for ChemoCentryx’s earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.19). ChemoCentryx posted earnings per share of ($0.12) in the same quarter last year, which would indicate a negative year over year growth rate of 141.7%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that ChemoCentryx will report full year earnings of ($1.18) per share for the current year, with EPS estimates ranging from ($1.31) to ($1.05). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.35) per share, with EPS estimates ranging from ($1.54) to ($1.15). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the consensus estimate of ($0.22) by $1.02. The firm had revenue of $56.30 million during the quarter, compared to the consensus estimate of $9.03 million.
Institutional investors and hedge funds have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership boosted its stake in shares of ChemoCentryx by 44.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 26,016 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 8,017 shares in the last quarter. Landscape Capital Management L.L.C. boosted its stake in shares of ChemoCentryx by 35.4% in the 4th quarter. Landscape Capital Management L.L.C. now owns 33,764 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 8,825 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of ChemoCentryx by 46.2% in the 3rd quarter. Wells Fargo & Company MN now owns 34,503 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 10,908 shares in the last quarter. Unterberg Capital LLC acquired a new stake in shares of ChemoCentryx in the 4th quarter valued at approximately $595,000. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of ChemoCentryx by 10.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 121,132 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 11,124 shares in the last quarter. Institutional investors own 48.24% of the company’s stock.
CCXI stock opened at $10.98 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.46 and a current ratio of 5.46. ChemoCentryx has a 12 month low of $5.42 and a 12 month high of $15.08. The stock has a market capitalization of $574.14, a price-to-earnings ratio of 32.50 and a beta of 1.56.
WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/04/17/chemocentryx-ccxi-expected-to-announce-earnings-of-0-29-per-share.html.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.